Lijun International Pharmaceutical (Holding) Co. Ltd.
Introduction '''Lijun International Pharmaceutical (Holding) Co., Limited''' () () is a Wanchai, Hong Kong-based investment holding company with two pharmaceutical business segments:
Business segments * manufacturing and selling of intravenous infusion solution* manufacturing and selling of antibiotics and othersThe Group was listed on Hong Kong Stock Exchange in December 2005 (stock code: 2005). The Group is engaged in the research, development, manufacturing and selling of a wide range of finished medicines and bulk pharmaceutical products to hospitals and distributors, including antibiotics, intravenous infusion solution, non-antibiotics finished products, bulk pharmaceuticals and health care product.
Subsidiaries The Company’s subsidiaries include:* New Orient Limited (New Orient) in Hong Kong* Shijiazhuang No. 4 Pharmaceutical Co., Limited, intravenous infusion solution manufacturer in Hebei Province (acquired in June 2007)* Xi’an Lijun Pharmaceutical Co., Limited (Xi’an Lijun), engaged in manufacturing pharmaceuticals in Shaanxi Province* Shenzhen Lijun Pharmaceutical Co., Limited, engaged in manufacturing pharmaceuticals in Guangdong Province.The Company is the largest domestic manufacturer of macrolide antibiotics, with a leading position for its intravenous infusion solution products in high-end hospital market. Facing more merger and acquisition opportunities from medical reform in China, the Group is positioned for continuous mergers and acquisitions to promote its growth.
External links * Lijun (Official website)* Xi'an Lijun website